This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by White, R. R. Articles by Tyler, D. S. Search for Related Content PubMed PubMed Citation Articles by White, R. R. Articles by Tyler, D. S.

Significance of Histological Response to Preoperative Chemoradiotherapy for Pancreatic Cancer

¹ Department of Surgery, Duke University Medical Center, Box 3118, Durham, North Carolina 27710,
² Department of Pathology, Duke University Medical Center, Box 3118, Durham, North Carolina
³ Department of Radiation Oncology, Duke University Medical Center, Box 3118, Durham, North Carolina
⁴ Department of Medicine, Duke University Medical Center, Box 3118, Durham, North Carolina
⁵ Department of Radiology, Duke University Medical Center, Box 3118, Durham, North Carolina

Correspondence: Address correspondence and reprint requests to: Douglas S. Tyler, MD; E-mail: tyler002{at}mc.duke.edu.

Background: Neoadjuvant (preoperative) chemoradiotherapy (CRT) for pancreatic cancer offers theoretical advantages over the standard approach of surgery followed by adjuvant CRT. We hypothesized that histological responses to CRT would be significant prognostic factors in patients undergoing neoadjuvant CRT followed by resection.

Methods: Since 1994, 193 patients with biopsy-proven pancreatic adenocarcinoma have completed neoadjuvant CRT, and 70 patients have undergone resection. Specimens were retrospectively examined by an individual pathologist for histological responses (tumor necrosis, tumor fibrosis, and residual tumor load) and immunohistochemical staining for p53 and epidermal growth factor receptor. Factors influencing overall survival were analyzed with the Kaplan-Meier (univariate) and Cox proportional hazards (multivariate) methods.

Results: The estimated overall survival (median ± SE) in the entire group of patients undergoing resection was 23 ± 4.2 months, with an estimated 3-year survival of 37% ± 6.6% and a median follow-up of 28 months. Complete histological responses occurred in 6% of patients. Overexpression of p53 was more common in patients with large residual tumor loads. Tumor necrosis was an independent negative prognostic factor, as were positive lymph nodes, a large residual tumor load, and poor tumor differentiation.

Conclusions: Histological response to neoadjuvant CRT—as measured by residual tumor load—may be useful as a surrogate marker for treatment efficacy. Characterization of the tumor cells that survive neoadjuvant CRT may help us to identify new or more appropriate targets for systemic therapy.

Key Words: Pancreatic cancer • Chemoradiotherapy • Neoadjuvant therapy • Histological response

This article has been cited by other articles:

				F. Cordera, C. A. Arciero, T. Li, J. C. Watson, and J. P. Hoffman Significance of Common Hepatic Artery Lymph Node Metastases During Pancreaticoduodenectomy for Pancreatic Head Adenocarcinoma Ann. Surg. Oncol., August 1, 2007; 14(8): 2330 - 2336. [Abstract] [Full Text] [PDF]

				R. R. White, M. W. Kattan, J. C. Haney, B. M. Clary, T. N. Pappas, D. S. Tyler, and M. F. Brennan Evaluation of Preoperative Therapy for Pancreatic Cancer Using a Prognostic Nomogram Ann. Surg. Oncol., November 1, 2006; 13(11): 1485 - 1492. [Abstract] [Full Text] [PDF]

				P. Massucco, L. Capussotti, A. Magnino, E. Sperti, M. Gatti, A. Muratore, E. Sgotto, P. Gabriele, and M. Aglietta Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival Ann. Surg. Oncol., September 1, 2006; 13(9): 1201 - 1208. [Abstract] [Full Text] [PDF]